Advanced search
Publication Cover
OncoTargets and Therapy Volume 16, 2023 - Issue
Submit an article Journal homepage
86
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Post-HSCT Maintenance Treatment Using Entrectinib for an AML Patient Accompanied with ETV6::NTRK3: A Case Report

Xiaoli Zhao1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, People’s Republic of China;2 Tianjin Institutes of Health Science, Tianjin, 301600, People’s Republic of ChinaView further author information
,
Mengze Hao1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, People’s Republic of China;2 Tianjin Institutes of Health Science, Tianjin, 301600, People’s Republic of ChinaView further author information
,
Xiaoyu Zhang1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, People’s Republic of China;2 Tianjin Institutes of Health Science, Tianjin, 301600, People’s Republic of ChinaView further author information
,
Jialin Wei1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, People’s Republic of China;2 Tianjin Institutes of Health Science, Tianjin, 301600, People’s Republic of ChinaView further author information
,
Sizhou Feng1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, People’s Republic of China;2 Tianjin Institutes of Health Science, Tianjin, 301600, People’s Republic of ChinaView further author information
,
Yi He1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, People’s Republic of China;2 Tianjin Institutes of Health Science, Tianjin, 301600, People’s Republic of ChinaCorrespondence[email protected]
View further author information
,
Erlie Jiang1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, People’s Republic of China;2 Tianjin Institutes of Health Science, Tianjin, 301600, People’s Republic of ChinaView further author information
&
Mingzhe Han1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, People’s Republic of China;2 Tianjin Institutes of Health Science, Tianjin, 301600, People’s Republic of ChinaView further author information
 show all
Pages 1055-1059 | Received 09 Aug 2023, Accepted 04 Dec 2023, Published online: 17 Dec 2023

References

  • Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discovery. 2015;5(1):25–34. doi:10.1158/2159-8290.CD-14-0765
  • Joshi SK, Davare MA, Druker BJ, Tognon CE. Revisiting NTRKs as an emerging oncogene in hematological malignancies. Leukemia. 2019;33(11):2563–2574. doi:10.1038/s41375-019-0576-8
  • Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731–747. doi:10.1038/s41571-018-0113-0
  • Taylor J, Pavlick D, Yoshimi A, et al. Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies. J Clin Investigation. 2018;128(9):3819–3825. doi:10.1172/JCI120787
  • Zhou F, Chen B. Acute myeloid leukemia carrying ETV6 mutations: biologic and clinical features. Hematology. 2018;23(9):608–612. doi:10.1080/10245332.2018.1482051
  • Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Eng j Med. 2018;378(8):731–739. doi:10.1056/NEJMoa1714448
  • Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three Phase 1-2 trials. Lancet Oncol. 2020;21(2):271–282. doi:10.1016/S1470-2045(19)30691-6
  • Roberts KG, Janke LJ, Zhao Y, et al. ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition. Blood. 2018;132(8):861–865. doi:10.1182/blood-2018-05-849554
  • Chen S, Zhang X, Zhai W, et al. P1390: the efficacy and safety of modified melphalan and busulfan-based regimen for allogeneic transplantation in refractory/relapsed AML patients. HemaSphere. 2022;6:1274–1275. doi:10.1097/01.HS9.0000848420.57492.c3
  • Pasvolsky O, Shimony S, Yeshurun M, et al. Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis. Acta oncologica. 2021;60(10):1335–1341. doi:10.1080/0284186X.2021.1955969
  • Rautenberg C, Germing U, Haas R, Kobbe G, Schroeder T. Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: prevention, Detection, and Treatment. Int J Mol Sci. 2019;20(1):228. doi:10.3390/ijms20010228
  • Setoyama M, Tojo A, Nagamura F, et al. A unique translocation of the TEL gene in a case of acute myelogenous leukemia with inv(12)(p13q15). Blood. 1998;92(4):1454–1455. doi:10.1182/blood.V92.4.1454
  • Kralik JM, Kranewitter W, Boesmueller H, et al. Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia. Diagn. Pathol. 2011;6(1):19. doi:10.1186/1746-1596-6-19
  • Smith KM, Fagan PC, Pomari E, et al. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia. Mol Cancer Therapeutics. 2018;17(2):455–463. doi:10.1158/1535-7163.MCT-17-0419
  • Frampton JE. Entrectinib: a Review in NTRK+ Solid Tumours and ROS1+ NSCLC. Drugs. 2021;81(6):697–708. doi:10.1007/s40265-021-01503-3

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.